-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $283

Benzinga·08/11/2026 15:51:08
Listen to the news
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $280 to $283.